Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14184491
Abstract: Simple Summary The biosynthesis of fatty acids catalysed by FASN plays an important oncogenic role in various malignancies but has not been reported in CTCL yet. Here, we show that FASN is highly expressed in… read more here.
Keywords: cell; ctcl; fasn srebp; inhibition fasn ... See more keywords